Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Other financing activities (2019 - 2025)

Historic Other financing activities for Heron Therapeutics (HRTX) over the last 7 years, with Q3 2025 value amounting to -$51000.0.

  • Heron Therapeutics' Other financing activities fell 49230.77% to -$51000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $168000.0, marking a year-over-year decrease of 5058.82%. This contributed to the annual value of $303000.0 for FY2024, which is 13355.48% up from last year.
  • Latest data reveals that Heron Therapeutics reported Other financing activities of -$51000.0 as of Q3 2025, which was down 49230.77% from $194000.0 recorded in Q2 2025.
  • Over the past 5 years, Heron Therapeutics' Other financing activities peaked at $4.2 million during Q2 2021, and registered a low of -$637000.0 during Q1 2022.
  • Over the past 5 years, Heron Therapeutics' median Other financing activities value was -$51000.0 (recorded in 2025), while the average stood at $158052.6.
  • In the last 5 years, Heron Therapeutics' Other financing activities crashed by 185000.0% in 2024 and then skyrocketed by 48181.82% in 2025.
  • Heron Therapeutics' Other financing activities (Quarter) stood at -$123000.0 in 2021, then crashed by 74.8% to -$215000.0 in 2022, then soared by 99.07% to -$2000.0 in 2023, then crashed by 1850.0% to -$39000.0 in 2024, then plummeted by 30.77% to -$51000.0 in 2025.
  • Its last three reported values are -$51000.0 in Q3 2025, $194000.0 for Q2 2025, and $64000.0 during Q1 2025.